There are other CAR treatments for other types of liquid tumors, such as natural killer group 2D (NKG2D) ligand-targeting therapies for acute myeloid leukemia, since NKG2D ligands are widely expressed in many malignancies and preclinical experiments with the respective CAR constructs showed promising results [74,75]. Here, KLRK1 is linked to acute myeloid leukemia.